Erlotinib Response in a Non-Small Cell Lung Cancer Patient with EGFR Exon 20 Mutation

References (10)

1. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mu- tations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306-13311, 2004.
2. Bircan S, Baloglu H, Kucukodaci Z, et al. EGFR and KRAS mutations in Turkish non-small cell lung cancer patients: a pilot study. Med Oncol 31: 87, 2014.
3. Jackman DM, Yeap BY, Sequist LV, et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 12: 3908- 3914, 2006.
4. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor recepıtor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 98: 1817-1824, 2007.
5. Fukuoka M, Yano S, Giaccone G, et al. Multiinstitutional rand- omized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21: 2237-2246, 2003.
6. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73, 2005.
7. Wang Y, Bao W, Shi H, et al. Epidermal Growth Factor Re- ceptor Exon 20 Mutation Increased in Post-Chemotherapy Patients with Non-Small Cell Lung Cancer Detected with Pa- tients' Blood Samples. Transl Oncol 6: 504-510, 2013.
8. Rosell R, Carcereny E, Gervais R, et al. Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo- Cancérologie and Associazione Italiana Oncologia Toracica Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutationpositive non-small-cell lung cancer (EURTAC): a multicentre, open- label, randomised phase 3 trial. Lancet Oncol 2012: 13: 239- 246, 2012.
9. Xing K, Zhou X, Zhao X, et al. A novel point mutation in exon 20 of EGFR showed sensitivity to erlotinib. Med Oncol 31: 36, 2014.
10. Arcila ME, Nafa K, Chaft JE, et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecu- lar heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther 12: 220-229, 2013.